These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36440483)

  • 1. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
    Salhotra A; Sandhu K; O'Hearn J; Ali H; Nakamura R; Modi BG
    Expert Rev Clin Immunol; 2023 Mar; 19(3):241-251. PubMed ID: 36440483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belumosudil for chronic graft-versus-host disease.
    Taylor B; Cohen J; Tejeda J; Wang TP
    Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China.
    Wang Y; Wu D; Zhang X; Li Y; He Y; Liu Q; Xuan L; Li Z; Qi K; Sun Y; Wang S; Mo W; Gao L; Hua Y; Wang Y; Zhang Y
    BMC Med; 2024 Mar; 22(1):142. PubMed ID: 38532458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
    Cutler C; Lee SJ; Arai S; Rotta M; Zoghi B; Lazaryan A; Ramakrishnan A; DeFilipp Z; Salhotra A; Chai-Ho W; Mehta R; Wang T; Arora M; Pusic I; Saad A; Shah NN; Abhyankar S; Bachier C; Galvin J; Im A; Langston A; Liesveld J; Juckett M; Logan A; Schachter L; Alavi A; Howard D; Waksal HW; Ryan J; Eiznhamer D; Aggarwal SK; Ieyoub J; Schueller O; Green L; Yang Z; Krenz H; Jagasia M; Blazar BR; Pavletic S
    Blood; 2021 Dec; 138(22):2278-2289. PubMed ID: 34265047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
    Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
    J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
    DeFilipp Z; Kim HT; Yang Z; Noonan J; Blazar BR; Lee SJ; Pavletic SZ; Cutler C
    Blood Adv; 2022 Dec; 6(24):6263-6270. PubMed ID: 36083121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
    Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates in chronic graft-versus-host disease management.
    Malard F; Mohty M
    Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belumosudil: First Approval.
    Blair HA
    Drugs; 2021 Sep; 81(14):1677-1682. PubMed ID: 34463931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.
    Zanin-Zhorov A; Blazar BR
    Clin Immunol; 2021 Sep; 230():108823. PubMed ID: 34400321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease.
    Gonzalez R; Gaskill E; Padilla M; Pidala J; Lazaryan A; Perez L; Khimani F; Faramand R
    Transplant Cell Ther; 2023 Sep; 29(9):577.e1-577.e9. PubMed ID: 37355201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
    Zeiser R
    J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Toubai T; Hosokawa Y
    Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States.
    Bachier CR; Skaar JR; Dehipawala S; Miao B; Ieyoub J; Taitel H
    J Med Econ; 2022; 25(1):857-863. PubMed ID: 35674411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.
    Ali F; Ilyas A
    Curr Res Transl Med; 2022 Jul; 70(3):103343. PubMed ID: 35339032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three US Food and Drug Administration-approved therapies for chronic GVHD.
    Zeiser R; Lee SJ
    Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
    Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
    Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
    Flynn R; Paz K; Du J; Reichenbach DK; Taylor PA; Panoskaltsis-Mortari A; Vulic A; Luznik L; MacDonald KK; Hill GR; Nyuydzefe MS; Weiss JM; Chen W; Trzeciak A; Serody JS; Aguilar EG; Murphy WJ; Maillard I; Munn D; Koreth J; Cutler CS; Antin JH; Ritz J; Waksal SD; Zanin-Zhorov A; Blazar BR
    Blood; 2016 Apr; 127(17):2144-54. PubMed ID: 26983850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
    Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
    Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.